Cybin Inc. (CYBN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Toronto, ON, Canada. The current CEO is Eric So.
CYBN has IPO date of 2019-09-13, 50 full-time employees, listed on the NYSE, a market capitalization of $413.02M.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
